| CVSS Meta Temp Score | Current Exploit Price (≈) | CTI Interest Score |
|---|---|---|
| 6.4 | $0-$5k | 0.00 |
Summary
A vulnerability was found in Liferay Portal and DXP and classified as critical. This vulnerability affects unknown code of the component SLO API. Such manipulation leads to session expiration. This vulnerability is listed as CVE-2025-43819. The attack may be performed from remote. There is no available exploit.
Details
A vulnerability, which was classified as critical, has been found in Liferay Portal and DXP (the affected version is unknown). Affected by this issue is an unknown code of the component SLO API. The manipulation with an unknown input leads to a session expiration vulnerability. Using CWE to declare the problem leads to CWE-613. According to WASC, "Insufficient Session Expiration is when a web site permits an attacker to reuse old session credentials or session IDs for authorization." Impacted is confidentiality, integrity, and availability. CVE summarizes:
A Insufficient Session Expiration vulnerability in the Liferay Portal 7.4.3.121 through 7.3.3.131, and Liferay DXP 2024.Q4.0 through 2024.Q4.3, 2024.Q3.1 through 2024.Q3.13, 2024.Q2.0 through 2024.Q2.13, and 2024.Q1.1 through 2024.Q1.12 is allow an remote non-authenticated attacker to reuse old user session by SLO API
The advisory is available at liferay.dev. This vulnerability is handled as CVE-2025-43819 since 04/17/2025. The exploitation is known to be easy. The attack may be launched remotely. The technical details are unknown and an exploit is not available. The structure of the vulnerability defines a possible price range of USD $0-$5k at the moment (estimation calculated on 12/16/2025).
There is no information about possible countermeasures known. It may be suggested to replace the affected object with an alternative product.
The vulnerability is also documented in the databases at CNNVD (CNNVD-202509-3899), EUVD (EUVD-2025-30940) and CERT Bund (WID-SEC-2025-2118). If you want to get best quality of vulnerability data, you may have to visit VulDB.
Affected
- Liferay Portal
- Liferay DXP
Product
Type
Vendor
Name
License
CPE 2.3
CPE 2.2
CVSSv4
VulDB Vector: 🔒VulDB Reliability: 🔍
CNA CVSS-B Score: 🔒
CNA CVSS-BT Score: 🔒
CNA Vector: 🔒
CVSSv3
VulDB Meta Base Score: 6.4VulDB Meta Temp Score: 6.4
VulDB Base Score: 6.3
VulDB Temp Score: 6.3
VulDB Vector: 🔒
VulDB Reliability: 🔍
NVD Base Score: 6.5
NVD Vector: 🔒
CVSSv2
| AV | AC | Au | C | I | A |
|---|---|---|---|---|---|
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| Vector | Complexity | Authentication | Confidentiality | Integrity | Availability |
|---|---|---|---|---|---|
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
VulDB Base Score: 🔒
VulDB Temp Score: 🔒
VulDB Reliability: 🔍
Exploiting
Class: Session expirationCWE: CWE-613
CAPEC: 🔒
ATT&CK: 🔒
Physical: No
Local: No
Remote: Yes
Availability: 🔒
Status: Not defined
EPSS Score: 🔒
EPSS Percentile: 🔒
Price Prediction: 🔍
Current Price Estimation: 🔒
| 0-Day | Unlock | Unlock | Unlock | Unlock |
|---|---|---|---|---|
| Today | Unlock | Unlock | Unlock | Unlock |
Threat Intelligence
Interest: 🔍Active Actors: 🔍
Active APT Groups: 🔍
Countermeasures
Recommended: no mitigation knownStatus: 🔍
0-Day Time: 🔒
Timeline
04/17/2025 CVE reserved09/24/2025 Advisory disclosed
09/24/2025 VulDB entry created
12/16/2025 VulDB entry last update
Sources
Advisory: liferay.devStatus: Confirmed
CVE: CVE-2025-43819 (🔒)
GCVE (CVE): GCVE-0-2025-43819
GCVE (VulDB): GCVE-100-325658
EUVD: 🔒
CERT Bund: WID-SEC-2025-2118 - Liferay Portal: Mehrere Schwachstellen
CNNVD: CNNVD-202509-3899 - Liferay Portal和Liferay DXP 代码问题漏洞
Entry
Created: 09/24/2025 07:50Updated: 12/16/2025 00:29
Changes: 09/24/2025 07:50 (64), 09/24/2025 12:49 (7), 09/25/2025 16:23 (6), 09/27/2025 11:47 (1), 12/16/2025 00:29 (11)
Complete: 🔍
Cache ID: 216::103
If you want to get best quality of vulnerability data, you may have to visit VulDB.
No comments yet. Languages: en.
Please log in to comment.